What were the key takeaways from PACS's earnings call?

What were the key takeaways from PACS’s earnings call?

What is the market's earnings forecast for PACS next quarter?

What does PACS do and what are its main business segments?

Did PACS beat or miss consensus estimates last quarter?

What guidance did PACS's management provide for the next earnings period?

What factors drove the changes in PACS's revenue and profit?

What is PACS's latest dividend and current dividend yield?

- **Record 2025 Performance**: $5.29B revenue (+29% YoY), 207 facilities (73.4%) with 4-5 star CMS ratings, and 0.3x net leverage.
- **2026 Growth Outlook**: $5.65-5.75B revenue (+8%), $555-575M EBITDA (+12%), targeting 8-10 acquisitions/year.
- **Clinical Excellence**: 5-star CMS rating improvement case study, 12%+ skilled mix growth in mature facilities.
- **Strategic Expansion**: 8 ground-up projects, 102 owned facilities, and selective real estate ownership to reduce lease costs.

**【CEO Opening Remarks】**
- Reported record 2025 results with $5.29 billion revenue (+29% YoY) and $191.5 million net income. 
- 207 facilities (73.4% of SNF portfolio) achieved 4-5 star CMS quality ratings, up from 68.5% in 2024.
- Highlighted a Kentucky facility that improved from 2-star to 5-star CMS rating within 1 year through data-driven clinical interventions.
- 2026 priorities include integrating 2024 acquisitions, pursuing 8-10 new acquisitions/year, and expanding real estate ownership.

**【CFO Financial Summary】**
- Q4 2025 revenue: $1.36 billion (+12% YoY)
- Full year 2025 metrics:
  - Adjusted EBITDAR: $883.9 million (+29% YoY)
  - Adjusted EBITDA: $505 million (+29% YoY)
  - Mature facilities occupancy: 94.9% (vs 94.4% 2024)
- 2026 guidance: 
  - Revenue: $5.65-5.75 billion (+8% YoY)
  - Adjusted EBITDA: $555-575 million (+12% YoY)
- Maintained conservative balance sheet with 0.3x net leverage and $145M+ 2025 capital deployment.

**【Q&A Highlights】**
- **Payer Strategy**: High clinical quality (e.g., 5-star CMS ratings) positions as preferred post-acute partner, driving 12%+ skilled mix growth in mature facilities.
- **M&A Pipeline**: 8-10 acquisitions/year targeting underperforming facilities (<70% occupancy) with 13+ year lease terms. 2026 already closed 3 Alaska/Idaho deals.
- **De Novo Development**: 8 ground-up projects since inception, with Oceanside CA facility achieving 1-year profitability. Will selectively pursue new builds in high-density markets.
- **Value-Based Purchasing**: Strong performance on new staffing-to-acuity and infection prevention measures positions for upside in TEAM model reimbursement.
- **Real Estate Strategy**: Increased ownership to 102 facilities (vs 82 in 2024), reducing lease-adjusted leverage while maintaining 13-year average lease term stability.

PACS Group, Inc. (PACS) Q4 2025 Earnings Call Transcript

- **Record Financial Performance**: Q3 2025 revenue up 31% YoY to $1.3B, adj. EBITDA $131.5M.
- **Operational Strength**: 89% total occupancy, 95% in mature facilities, 25% skilled mix in new facilities.
- **Disciplined Growth**: 7 acquisitions YTD, 36 leadership pipeline candidates, 100 owned/partially owned facilities.
- **Clinical Excellence**: 192 facilities (68.6%) with 4/5-star CMS ratings, 5 special focus facilities graduated.
- **Cash Position**: $355.7M as of Q3, $407M YTD cash flow from operations.

**【Management Opening Remarks】**
- PACS Group completed restatements and strengthened internal controls, emphasizing transparency and governance.
- Independent investigation concluded, reinforcing commitment to accountability and strong governance.
- Investor presentation and earnings release available with non-GAAP financial measures reconciliation.

**【CEO Commentary】**
- Delivered record Q3 and YTD 2025 results: $1.3B revenue (31% YoY), $131.5M adj. EBITDA, and 89% total occupancy.
- Acquired 7 facilities YTD 2025, expanding to 32 states with 35,202 beds.
- Mature facilities achieve 95% occupancy, while new facilities (81%) show improvement in skilled mix (25% vs. 22% YoY).
- AIT program trains 36 leaders, supporting growth and operational excellence.
- Colorado facility turnaround exemplifies ability to transform underperforming assets.

**【CFO Financial Commentary】**
- Q3 2025: $1.3B revenue, $226.6M adj. EBITDAR, $52.3M net income, $0.32 EPS.
- YTD 2025: $3.9B revenue (36% YoY), $646.2M adj. EBITDAR, $131.7M net income.
- Cost of services up 32% YoY due to staffing and quality investments.
- Owned/partially owned real estate for 100 facilities, with 13-year lease average.
- Full-year 2025 guidance: $5.25B-$5.35B revenue, $480M-$490M adj. EBITDA.

**【Q&A Highlights】**
- Occupancy trends: New facilities improving, mature facilities stable at 95%.
- M&A pipeline: 7 acquisitions YTD, targeting 20-30/year with disciplined approach.
- Cash flow: $407M YTD from operations, $355.7M cash as of Q3.
- Medicaid: Focus on states with case mix incentives (e.g., Kentucky, Ohio), 2%-3% margin for new facilities.
- Compliance: Enhanced controls support local leadership, maintaining strong referral relationships.


Actual	0.38	0.56	0.32	0.461
Forecast	0.2924	0.3528	0.45	0.4642
Surprise	+29.96%	+58.73%	-28.89%	-0.69%

Actual	934.72M	981.85M	1.34B	1.37B
Forecast	883.38M	919.22M	1.11B	1.38B
Surprise	+5.81%	+6.81%	+20.98%	-0.86%

PACS

PACS fundamentals

PACS Q4 2025 Earnings

Earnings Call

You can ask Aime

PACS

PACS fundamentals

PACS Q4 2025 Earnings

Earnings Call

PACS Earnings Call Summary for Q4/20255:30 PM on Feb 26, 2026

PACS Earnings Call Summary for Q3/20255:30 PM on Nov 19, 2025

PACS Earnings Call Summary for Q2/20245:00 PM on Aug 12, 2024

PACS Earnings Call Summary for Q1/20244:00 PM on May 14, 2024

You can ask Aime